CAMBRIDGE, Mass. — Predicta Biosciences has appointed Craig L. Tendler, M.D., as an independent director to its board of directors.
The Cambridge-based company, which is developing ultra-sensitive molecular and immune diagnostic platforms, said Tendler brings decades of experience in oncology and hematology drug development, including work involving biomarkers and diagnostics from early development through regulatory approval.
Tendler has played a leadership role in more than 30 major drug approvals by national regulatory agencies, including the U.S. Food and Drug Administration, and 13 FDA Breakthrough Therapy designations. Predicta said his experience will support the company as it advances diagnostic tools intended to help guide treatment decisions for patients with cancer.
“We are honored to welcome Dr. Tendler to Predicta’s Board,” said Brian McKernan, CEO of Predicta Biosciences. “Craig’s perspective will be invaluable as Predicta continues to advance innovations that help ensure more patients have access to lifesaving diagnostics.”
Predicta’s platforms include GenoPredicta and ImmunoPredicta, which the company said are designed to support informed clinical decisions for patients with multiple myeloma.
“I am delighted to be joining Predicta’s world-class team of clinical, genomic, and bioinformatic leaders who have already advanced two platforms, GenoPredicta and ImmunoPredicta, which can greatly aid in making informed clinical decisions for patients with multiple myeloma,” said Tendler. “I look forward to integrating these important platforms across drug development programs in heme malignancies to increase the probability of success and improve outcomes for patients.”
Tendler most recently served as vice president of oncology clinical development, diagnostics and global medical affairs at the Janssen Pharmaceutical Companies of Johnson & Johnson. He previously served as vice president of oncology clinical research at the Schering-Plough Research Institute.
He also has served as an assistant professor of pediatrics at the Icahn School of Medicine at Mount Sinai in New York City and was a research fellow at the National Cancer Institute in Bethesda, Md.
